NCT00638937CompletedPhase 2

A Phase 2 Study of AZD0530 in Patients With Advanced, Recurrent Non-Small Cell Lung Cancer Who Have Previously Received Platinum-Based Combination Chemotherapy

National Cancer Institute (NCI)4 sites in 1 country37 target enrollmentStarted: February 2008Last updated: August 29, 2018

Conditions

Interventions

Drugs

Trial Snapshot

Phase: Phase 2
Status: Completed
Sponsor: National Cancer Institute (NCI)
Enrollment: 37
Locations: 4
Primary Endpoint: Rate of Disease Control (Freedom From Disease Progression)

Study Overview Study Design Eligibility Criteria Arms & Interventions Outcomes Investigators Sites Records & Identifiers Similar Trials

Study Overview

Brief Summary

This phase II trial is studying how well saracatinib works in treating patients with recurrent, stage IIIB or stage IV non-small cell lung cancer previously treated with combination chemotherapy that included cisplatin or carboplatin. Saracatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Detailed Description

PRIMARY OBJECTIVES:

I. Assess the rate of disease control (i.e., lack of disease progression, a combined rate of objective complete and partial response, and stable disease) for at least 4 cycles of therapy in patients with AZD0530 (saracatinib) in patients with advanced non-small cell lung cancer that had previously been treated with platinum-based combination chemotherapy.

SECONDARY OBJECTIVES:

I. To assess the objective response rate (complete and partial response), stable disease rate, duration of response or stable disease, progression-free, median and 6 month overall survival rates, safety and tolerability of this treatment.

TERTIARY OBJECTIVES:

Study Design

Study Type: Interventional
Allocation: Na
Intervention Model: Single Group
Primary Purpose: Treatment
Masking: None

Eligibility Criteria

Ages: 18 Years to — (Adult, Older Adult)
Sex: All
Accepts Healthy Volunteers: No

Inclusion Criteria

•Recurrent/metastatic/locally advanced unresectable, histologically or cytologically confirmed NSCLC
•Measurable disease defined (RECIST) as at least 1 lesion measured in at least 1 dimension (longest diameter) as >20mm with conventional techniques or >10mm with spiral CT scan
•Previously treated with firstline platinum-based systemic chemotherapy for advanced disease AND had at least disease stabilization as best response to firstline therapy
•<=1 line of prior therapy
•Not have had prior treatment with EGFR Tyrosine kinase inhibitor
•Completed chemotherapy/surgery/radiotherapy 4 weeks before study entry and must have recovered from toxic effects of prior therapy
•Had >40% of their bone marrow radiated and must have either measurable disease outside field/documented progression post radiation therapy
•Life expectancy >3 months
•ECOG performance status =<2 OR Karnofsky >=60%
•Leukocytes >=3x10^9/L
•Absolute neutrophil count >=1.5x10^9/L
•Platelet count >=10x10^9/L
•Hemoglobin >9g/dL (may be transfused to meet this)
•Total bilirubin =<1.5 times institutional ULN (IULN)
•AST/ALT =<2.5xIULN (=<5 times ULN in the presence of liver metastases)
•Creatinine =<1.5xIULN OR creatinine clearance >=50 mL/min/1.73m^2
•Urine protein creatinine ratio =<1.0 OR urine protein >1.0, 24 hour urine for protein should be <1000mg
•Women of childbearing potential/men must use adequate contraception (hormonal/barrier method of birth control; abstinence) prior to study entry, for duration of study participation, and for 8 weeks following cessation of study therapy
•Ability to understand/willingness to sign written informed consent

Exclusion Criteria

•Chemotherapy/radiotherapy within 4 weeks (6 weeks for nitrosoureas/mitomycin C) prior to study entry/not recovered from AEs due to agents administered > than 4 weeks earlier
•No CYP3A4-active agents permitted during protocol treatment. Patients requiring treatment with these agents are not eligible; prohibited drugs should be discontinued 7 days before first dose of AZD0530 and for 7 days after discontinuation of AZD0530
•Cannot receive other investigational agents
•History of allergic reactions attributed to compounds of similar chemical/biologic composition to AZD0530
•QTc prolongation (i.e.QTc interval >=460 msec)/other significant ECG abnormalities
•Poorly controlled hypertension (i.e.systolic BP of 140 mmHg or higher, diastolic BP of 90mm Hg or higher)
•Any condition impairing ability to swallow AZD0530 tablets
•Treated brain metastases which are clinically and radiologically stable are permitted; patients requiring steroids/with neurological symptoms should be excluded because of poor prognosis/often develop progressive neurologic dysfunction
•Intercurrent cardiac dysfunction including but not limited to symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia are excluded as are those with ischemic heart disease history including myocardial infarction
•Uncontrolled intercurrent illness including but not limited to ongoing/active infection or psychiatric illness/social situations that would limit compliance with study requirements
•Pregnant women excluded because AZD0530 has potential teratogenic/abortifacient effects; because unknown but potential risks for AEs in nursing infants secondary to treatment of mother with AZD0530, breastfeeding should be discontinued if mother is treated with AZD0530
•HIV-positive patients on combination antiretroviral therapy are ineligible because potential for PK interactions with AZD0530; these patients have increased risk of lethal infections when treated with marrow-suppressive therapy; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated

Arms & Interventions

Treatment (saracatinib)

Experimental

Patients receive saracatinib PO, at a dose of 175 mg QD on days 1-28. Courses repeat every 28 days in the absence of unacceptable toxicity or disease progression

Intervention: saracatinib (Drug)

Outcomes

Primary Outcomes

Rate of Disease Control (Freedom From Disease Progression)

Time Frame: 112 days

Lack of disease progression, a combined rate of objective complete (disapprearance of all target lesions) and partial responses (\>= 30% decrease in sum of longest diameter of target lesions) and stable disease as determined by Response Evaluation Criteria in Solid Tumours (RECIST 1.0) for at least 4 cycles (16 weeks) of therapy. Standard descriptive statistics, such as the mean, median, range and proportion, will be used to summarize the patient sample and to estimate parameters of interest. Ninety-five percent confidence intervals will be provided for estimates of interest where possible.

Secondary Outcomes

Duration of Response or Stable Disease(From first response until the criteria for progression are met, assessed up to 1 year)
Median Progression-free Survival(From the date of study enrollment to the time the criteria for disease progression are met, death or last contact, or the last tumor assessment before the initiation of further anticancer therapy, assessed up to 1 year)
Stable Disease Rate(From the start of the treatment until the criteria for progression are met, assessed up to 1 year)
Objective Response Rate (Complete and Partial Response)(From the start of the treatment until the criteria for response are met)
Progression-free Survival(6 months)
Median Overall Survival(Up to 1 year)
Overall Survival(1 year)

Investigators

Sponsor

National Cancer Institute (NCI)

Sponsor Class

Nih

Responsible Party

Sponsor

Study Sites (4)

Loading locations...

Similar Trials

Completed

Phase 2

Saracatinib in Treating Patients With Previously Treated Metastatic Pancreatic CancerAdenocarcinoma of the PancreasRecurrent Pancreatic CancerStage IV Pancreatic Cancer

NCT00735917National Cancer Institute (NCI)19

Terminated

Phase 2

Saracatinib in Treating Patients With Relapsed or Refractory Thymoma or Thymic CancerInvasive Thymoma and Thymic CarcinomaRecurrent Thymoma and Thymic CarcinomaStage III ThymomaStage IVA ThymomaStage IVB Thymoma

NCT00718809National Cancer Institute (NCI)21

Completed

Phase 2

NCT00513435National Cancer Institute (NCI)9

Completed

Phase 2

Saracatinib in Treating Patients With Locally Advanced or Metastatic Stomach or Gastroesophageal Junction CancerAdenocarcinoma of the Gastroesophageal JunctionAdenocarcinoma of the StomachRecurrent Gastric CancerStage III Gastric CancerStage III Esophageal CancerStage IV Esophageal CancerStage IV Gastric Cancer

NCT00607594National Cancer Institute (NCI)21

Terminated

Phase 2

AZD0530 (NSC 735464) in Treating Patients With Previously Treated Metastatic Colon Cancer or Rectal CancerAdenocarcinoma of the ColonAdenocarcinoma of the RectumRecurrent Colon CancerRecurrent Rectal CancerStage IV Colon CancerStage IV Rectal Cancer

NCT00397878National Cancer Institute (NCI)10